Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anterios Inc.

Division of Allergan PLC
www.anteriosinc.com

Latest From Anterios Inc.

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.

Aesthetics Business Strategies

Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Dermatology Market Intelligence

Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.

Commercial Deals

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Encapsion
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Jon Edelson, MD, Pres. & CEO
    Klaus Theobald, MD, PhD, Chief R&D Officer
  • Contact Info
  • Anterios Inc.
    Phone: (212) 303-1683
    60 East 42nd St.
    Ste. 1160
    New York, NY 10165
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register